Saturday, 3 October 2026European Markets

IDEX BIOMETRICS Stock Was Up By 11.35% Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with IDEX BIOMETRICS (IDEX.OL) rising 11.35% to kr0.20 on Friday, after three consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI jumped 0.4% to kr1,449.34, after two sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.

IDEX BIOMETRICS's last close was kr0.18, 94.33% under its 52-week high of kr3.23.

About IDEX BIOMETRICS

IDEX Biometrics ASA, together with its subsidiaries, designs, develops, and sells fingerprint authentication solutions in Norway, Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's fingerprint authentication solutions are used primarily in contactless smart cards, that includes financial payment and access control cards, as well as card-based devices for the storage of digital currencies. It primarily serves smart card manufacturers and similar solution integrators. The company was incorporated in 1996 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, IDEX BIOMETRICS has a trailing twelve months EPS of kr-1.07.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -217.51%.

Moving Average

IDEX BIOMETRICS's worth is way under its 50-day moving average of kr0.67 and way below its 200-day moving average of kr1.62.

Yearly Top and Bottom Value

IDEX BIOMETRICS's stock is valued at kr0.20 at 22:30 EST, way under its 52-week high of kr3.23 and way higher than its 52-week low of kr0.17.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, IDEX BIOMETRICS's stock is considered to be overbought (>=80).

More news about IDEX BIOMETRICS (IDEX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com